Penile PRP Injection in 2026: What the Research Actually Shows

Introduction: The P-Shot Promise vs. The P-Shot Proof

Marketing for penile PRP injection, commonly branded the P-Shot or Priapus Shot, has quietly merged two very different promises into one. The first is restoring erectile function. The second is making the penis bigger. Many clinic websites present them as a single benefit, as if one injection naturally delivers both.

For high-earning, image-conscious professionals, this distinction matters. These are men who research before they spend, read the fine print, and expect evidence to match claims. Many have privately struggled with confidence for years without believing a credible solution existed. They deserve a clear-eyed look at what double-blind trials actually found compared with what clinic marketing implies.

This article separates the function claim from the size claim using the primary literature. It then offers a three-tier framework (PRP under research protocols, hyaluronic acid filler for girth, and surgery for extreme cases) so readers can match the option to their actual goal.

One point of transparency: Penis Enlargement New York City, operated by Stoller Medical Group, does not offer PRP. The goal here is education and honest triage, not a pitch for a treatment the data does not yet support for enlargement.

What Penile PRP Injection Actually Is

Platelet-rich plasma (PRP) is prepared from the patient’s own blood. A sample is drawn, spun in a centrifuge to concentrate the platelets, and the resulting plasma is injected into the penile shaft and/or glans.

The theoretical mechanism is regenerative. Platelets release growth factors proposed to stimulate angiogenesis (new blood vessel formation) and tissue repair. PRP is, at its core, a biologic approach that attempts to encourage the body’s own healing processes.

That is fundamentally different from a dermal filler. PRP does not physically add material or occupy space under the skin. It is not a volumizing agent. Any change it produces depends on how the body’s tissue responds, which varies widely from person to person.

Regulatory Reality: What Is Actually FDA Cleared

PRP for erectile dysfunction or penile enlargement is not FDA-approved as a treatment.

The confusion usually comes from device clearance. The FDA has cleared the centrifuges and blood-processing systems used to prepare PRP. That clearance covers the equipment, not the practice of injecting PRP into the penis for sexual-health indications.

Consumer-facing marketing rarely explains this nuance. A phrase like “FDA-cleared system” can easily be read as “FDA-approved treatment.” Understanding the difference is a key piece of due diligence before booking any appointment.

The Two Claims Marketing Conflates, and Why That Matters

The core thesis of this article is simple: “PRP heals erectile tissue” and “PRP enlarges the penis” are treated by clinic marketing as one bundled claim, yet they rest on entirely separate bodies of evidence of very different quality.

The Cleveland Clinic’s position is direct. According to its patient resource on the Priapus Shot, there is not good evidence that the P-Shot treats penile conditions, and the claim that it increases length or girth “isn’t supported by any scientific evidence.”

The next two sections function as a side-by-side evidence audit, function first and size second, so readers can see exactly where the data diverges.

What the Research Actually Shows: PRP for Erectile Function

Erectile function is the application where PRP has genuine double-blind, placebo-controlled randomized trial data. That places it in a materially higher evidence tier than the enlargement claim, even though the results themselves are not consistent.

The Two Conflicting Double-Blind RCTs

• Poulios et al. (2021): At six months, 69% of men in the PRP group reached a minimally clinically important difference (MCID) in erectile function scores, compared with 27% of the placebo group. This was a positive result.
• Ramasamy/Miami trial (2023): In 61 men with mild-to-moderate ED, published in The Journal of Urology, researchers found no statistically significant difference between PRP and placebo (58.3% vs. 53.6% reaching MCID). The senior author told Urology Times that PRP “does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy.”

The honest takeaway: two rigorous trials, run differently, reached opposite conclusions. This is genuinely unsettled science, not a definitive win for either side.

What the 2024 Meta-Analysis Adds

A 2024 meta-analysis published in PLOS ONE, pooling controlled and single-arm trials, found a statistically significant benefit for PRP over control (standardized mean difference of 0.59).

The authors themselves, however, called for larger, longer, higher-quality trials before firm conclusions can be drawn. Pooled significance across studies of mixed design does not resolve the conflict between the two best-controlled trials.

How Medical Societies Classify PRP for Function

The American Urological Association (AUA) erectile dysfunction guideline and the Sexual Medicine Society of North America (SMSNA) 2019 position statement both classify PRP, alongside low-intensity shockwave therapy and stem cell therapy, as “restorative/regenerative” but experimental.

Both bodies recommend that PRP be confined to research protocols rather than marketed as a routine cash-pay service. The SMSNA statement says restorative therapies “should remain strictly experimental and be reserved for clinical trials.” That is a meaningful departure from how PRP is commonly sold.

Research continues. Registered trials such as NCT07863388 and NCT07124871 are studying PRP and PRP-derived exosomes for post-prostatectomy and vasculogenic ED. The science is actively evolving, which also means it is not settled.

What the Research Actually Shows: PRP for Size

Here is the central point: neither randomized, double-blind PRP-for-ED trial measured penile length or girth as an outcome at all. The clinical research community studying PRP has not treated it as a sizing intervention.

The Only Study That Ever Measured Size Change

The single study aimed at size is the “P-Long” protocol, a small, unblinded pilot (mean patient age 32) presented in the Journal of Sexual Medicine supplement. It reported roughly 0.81 inches of length gain and 0.47 inches of girth gain over six months.

This sits at the bottom of the evidence hierarchy for several reasons:

• Self-measured, self-reported outcomes, which are vulnerable to measurement error and expectation bias
• No control group, so there is no way to separate treatment effect from placebo or natural variation
• Conference abstract only, never published as a full peer-reviewed paper

Compare that single low-tier abstract with the dozens of marketing pages citing similar numbers as if they were established clinical fact.

Why Clinics Can Still Advertise Size Gains

Marketing-forward clinic blogs extrapolate from patient anecdotes and the lone pilot abstract into firm promotional claims, such as a “1.5 inch increase after 6 treatments.” Before-and-after narratives are presented as outcomes rather than as stories.

The Cleveland Clinic position remains the counterweight: no scientific evidence supports the size claim. This gap between marketing and evidence is exactly why a decision framework, rather than a blanket yes or no, is the responsible way to approach the topic.

A Secondary Use Case: PRP for Peyronie’s Disease

Peyronie’s disease, a condition involving fibrous plaque and penile curvature, is where PRP has its most consistent, if still modest, data. Retrospective cohorts and small RCTs report statistically significant reductions in curvature and plaque size with intralesional PRP, along with a favorable safety profile.

Even here, the AUA and the European Association of Urology still label PRP “experimental.” The data is supportive, not definitive.

Most girth-focused content ignores this use case entirely. For men whose concern is curvature or a structural issue, rather than function or size, it is the most relevant PRP application to discuss with a urologist.

The Credentialing Problem: What the JAMA “Secret Shopper” Study Found

A cross-sectional study in JAMA Network Open had researchers pose as patients and contact 109 U.S. clinics offering PRP for ED. Only 9% of providers were urologists, and 22% were non-physicians.

The practical implication is that the direct-to-consumer PRP market varies widely in who performs the injection and under what protocol. Two clinics charging similar prices may operate under completely different standards.

A sound due-diligence checklist includes:

1. Provider specialty and board certification. Who is performing the injection, and what is their training in male anatomy?
2. Protocol source. Does the treatment follow a published research protocol or a registered clinical trial?
3. Outcome measurement. How are results measured and documented, rather than simply promised?

The Three-Tier Decision Framework: Matching the Treatment to the Actual Goal

Rather than issuing a yes-or-no verdict on PRP, the more useful approach is to sort by what a man is actually trying to solve: function and healing, size, or extreme anatomical correction.

Each tier is mechanism-matched to its goal. PRP’s biologic mechanism targets function and tissue response. Filler’s volumetric mechanism targets size. Surgery addresses anatomical extremes that neither injectable approach can.

Tier 1: PRP for Function and Healing, Under Research Protocols

Appropriate candidate: Men primarily concerned with erectile function or Peyronie’s-related curvature who understand that the evidence is mixed and early-stage.

Practical guidance: Seek providers operating under, or explicitly referencing, a registered clinical trial or research protocol, consistent with AUA and SMSNA recommendations that PRP remain investigational.

Key realities: PRP is not FDA-approved for this use. Sessions commonly cost $1,500 to $2,500 and are not covered by insurance. Results are not guaranteed, given the conflicting RCT data.

Tier 2: HA Filler for Evidence-Backed Girth Gain

The mechanistic contrast is plain: PRP attempts to encourage the body’s own tissue response, while HA filler physically occupies subcutaneous space between the dartos fascia and Buck’s fascia, directly adding volume.

The evidence base is considerably more aligned with the size goal:

• Randomized data: An 18-month Korean multicenter RCT found that both HA and polylactic acid (PLA) fillers produced significant, durable girth gains and improved satisfaction. A later systematic review and meta-analysis found HA outperformed PLA on girth gain.
• Real-world audits: A 324-patient audit reported a mean flaccid girth increase of 2.5 cm (range 1.5 to 4 cm) using roughly 15 mL of filler, with results lasting approximately 9 to 24 months. A separate 155-patient review of sequential treatments reported an average gain of 1.8 cm, rising to nearly 3 cm in patients who received four or more sessions.
• Manageable complications: Reported migration (about 7.7%) and lumps (about 4.6%) are reversible with hyaluronidase, the enzyme that dissolves HA.

Rigor in this space is increasing. Devices such as HYAcorp MLF1 and PhalloFILL are now in formal trials (including NCT07877077), and a review of roughly 500 patients presented at SMSNA found HA girth enhancement appeared safe with limited adverse events. Sample sizes in blinded filler studies remain modest, but the evidence is specifically designed to measure girth, the outcome size-focused patients actually care about.

Pricing, stated transparently: Treatment is priced by syringe and starts at $7,500, with cost increasing based on desired results. Most men require a minimum of 10 syringes, and the average first procedure uses 15 syringes.

At Stoller Medical Group, treatment is staged and conservatively planned for proportion and symmetry, with the practice reporting more than 15,000 enlargement procedures to date. For men whose primary goal is measurable, evidence-backed girth enhancement rather than functional repair, this tier is the appropriate path.

Tier 3: Surgery for Extreme Anatomical Cases

Surgical intervention becomes a consideration for severe anatomical concerns, such as significant congenital or acquired structural issues that fall outside what injectables can address.

Surgical lengthening and enlargement carry a materially higher risk profile and recovery burden than injectable options. For that reason, Penis Enlargement New York City does not offer surgical penile lengthening. The decision reflects safety-first triage logic, not revenue-first logic, and men who genuinely need surgical evaluation are best served by a specialized urologic surgeon.

Cost Is Not the Differentiator; Evidence Quality Is

A common assumption is that PRP is “worth trying because it’s cheaper.” P-Shot sessions commonly run $1,500 to $2,500, often repeated across multiple sessions. HA filler girth treatment starts at $7,500, priced by syringe, with a minimum of 10 and an average of 15 syringes for a first procedure. Neither is covered by insurance.

For high-income professionals, the decision-driving variable at this price range should be which body of evidence actually supports the outcome being sought. Paying less for a treatment with no supporting data for the intended goal is not a savings.

The three-tier framework applies here as well: choose based on matched mechanism and evidence tier, not perceived affordability.

Conclusion: Choosing Based on Evidence, Not Marketing Bundling

PRP’s function-related evidence is genuinely mixed, with two conflicting double-blind RCTs and a cautiously positive meta-analysis. Its size-related evidence is essentially a single unblinded pilot abstract. These are not interchangeable claims, and they should not be sold as one.

Credentialing matters as much as mechanism. The JAMA finding that only 9% of PRP-for-ED providers were urologists is a reminder that who performs a procedure, and under what protocol, shapes outcomes.

The practical takeaway:

• PRP under research protocols for function and healing
• HA filler for evidence-backed girth gain
• Surgery reserved for extreme anatomical cases

The underlying goal for most men is not a specific branded procedure. It is confidence, backed by a clear decision matched to the outcome they actually want.

Ready to Explore an Evidence-Backed Path to Results?

For men whose goal is measurable, documented girth enhancement, Stoller Medical Group offers a free consultation to discuss HA filler treatment planning, syringe-based pricing (starting at $7,500, with most men beginning at a minimum of 10 syringes and an average of 15 during the first procedure), and realistic expectations based on individual anatomy.

Consultations are private and discreet, built around individualized planning rather than one-size-fits-all promises. With locations in Manhattan, Long Island, Albany, Pennsylvania, and Minnesota, men ready to move from research to a real conversation with an experienced provider can do so close to home.